Mehr »
Freitag, 26.02.2021 Börsentäglich über 12.000 News von 656 internationalen Medien
Adhoc-Meldung: Eine ganz große Überraschung!



24 h / 7 T
7 Tage



24 h / 7 T
7 Tage











Erweiterte Suche

WKN: A2QJR8 ISIN: US42237K4094 Ticker-Symbol: 1HB 
21:39 Uhr
6,480 Euro
-6,63 %
1.252 Leser
Artikel bewerten:

Heat Biologics, Inc.: Heat Biologics Commences Manufacturing Process for ZVX-60

DURHAM, NC / ACCESSWIRE / January 19, 2021 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announces it has transferred its gp96-based COVID-19 vaccine cell line ("ZVX-60") to Waisman Biomanufacturing to initiate the manufacturing process for ZVX-60, which is being developed for use as either a standalone vaccine, or in combination with other vaccines, to enhance prophylactic protection against COVID-19.

Jeff Wolf, Heat's CEO, commented, "Initiation of our manufacturing process is an important milestone as we progress ZVX-60 into human clinical trials. As previously announced, recent data generated with our collaborators at the University of Miami Miller School of Medicine confirmed ZVX-60 expression of gp96, OX40L and the COVID-19 Spike protein. We believe ZVX-60 holds promise to enhance protection as a stand-alone vaccine or in combination with other vaccine approaches, and look forward to working with Waisman to manufacture ZVX-60 for our first-in-human clinical trial."

About Heat Biologics, Inc.

Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The company's gp96 platform is designed to activate immune responses against cancer or pathogenic antigens. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in its Phase 2 trial, HS-130 in Phase 1, and a COVID-19 vaccine program in preclinical development. In addition, Heat is also developing a pipeline of proprietary immunomodulatory antibodies, including PTX-35 which is enrolling in a Phase 1 trial.

For more information, please visit:, and also follow us on Twitter.

Forward Looking Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 on our current expectations and projections about future events. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectation, and assumptions and include statements such as ZVX-60 holding promise to enhance protection as a stand-alone vaccine or in combination with other vaccine approaches and the gp96 platform activating immune responses against cancer or pathogenic antigens. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including the ability of ZVX-60 to enhance protection as a stand-alone vaccine or in combination with other vaccine approaches, the ability of Heat's therapies to perform as designed, to demonstrate safety and efficacy, as well as results that are consistent with prior results, the ability to enroll patients and complete the clinical trials on time and achieve desired results and benefits, especially in light of COVID-19, Heat's ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to Heat's ability to promote or commercialize its product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, Heat's ability to maintain its license agreements, the continued maintenance and growth of its patent estate, its ability to establish and maintain collaborations, its ability to obtain or maintain the capital or grants necessary to fund its research and development activities, its ability to continue to maintain its listing on the Nasdaq Capital Market and its ability to retain its key scientists or management personnel, and the other factors described in Heat's most recent annual report on Form 10-K filed with the SEC, and other subsequent filings with the SEC. The information in this release is provided only as of the date of this release, and Heat undertakes no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.

Media and Investor Relations Contact

David Waldman
+1 919 289 4017

Consolidated Balance Sheets

September 30, December 31,
2020 2019
Current Assets
Cash and cash equivalents
$24,808,083 $9,039,887
Short-term investments
92,501,019 5,713,922
Accounts receivable
212,141 34,986
Prepaid expenses and other current assets
1,620,504 420,328
Total Current Assets
119,141,747 15,209,123
Property and Equipment, net
720,396 559,410
Other Assets
In-process R&D
5,866,000 5,866,000
1,452,338 1,452,338
Operating lease right-of-use asset
2,123,414 2,287,500
Finance lease right-of-use asset
276,918 187,573
129,505 394,637
Total Other Assets
9,848,175 10,188,048
Total Assets
$129,710,318 $25,956,581
Liabilities and Stockholders' Equity
Current Liabilities
Accounts payable
$753,872 $1,503,342
Deferred revenue, current portion
1,166,481 3,410,319
Contingent consideration, current portion
- 1,124,970
Contingent consideration, related party - current portion
- 454,364
Operating lease liability, current portion
271,703 216,832
Finance lease liability, current portion
106,409 49,104
Accrued expenses and other liabilities
1,503,899 1,676,467
Total Current Liabilities
3,802,364 8,435,398
Long Term Liabilities
Other long-term liabilities
26,331 -
Derivative warrant liability
60,915 -
Deferred tax liability
361,911 361,911
Deferred revenue, net of current portion
240,000 200,000
Operating lease liability, net of current portion
1,374,141 1,519,574
Financing lease liability, net of current portion
187,881 142,667
Contingent consideration, net of current portion
2,131,830 1,653,197
Contingent consideration, related party - net of current portion
626,685 485,984
Total Liabilities
8,812,058 12,798,731
Commitments and Contingencies (Note 13)
Stockholders' Equity
Common stock, $.0002 par value; 250,000,000 shares authorized, 157,021,194 and 33,785,999 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively
31,402 6,757
Additional paid-in capital
245,740,939 118,173,843
Accumulated deficit
(124,195,893) (104,597,748)
Accumulated other comprehensive loss
(35,910) (11,250)
Total Stockholders' Equity - Heat Biologics, Inc.
121,540,538 13,571,602
Non-Controlling Interest
(642,278) (413,752)
Total Stockholders' Equity
120,898,260 13,157,850
Total Liabilities and Stockholders' Equity
$129,710,318 $25,956,581

Consolidated Statements of Operations and Comprehensive Loss (unaudited)

Three Months Ended Nine Months Ended
September 30, September 30,
Grant and contract revenue
Operating expenses:
Research and development
General and administrative
Goodwill impairment loss
Change in fair value of contingent consideration
Total operating expenses
Loss from operations
Change in fair value of warrant liability
Investor relations expense
Interest income
Other income (expense), net
Total non-operating income (loss)
Net loss before income taxes
Income tax expense
Net loss
Net loss - non-controlling interest
Net loss attributable to Heat Biologics, Inc.
Net loss per share attributable to Heat Biologics, Inc.-
Net loss per share attributable to Heat Biologics, Inc.-basic and diluted
Weighted-average number of common shares used in net loss per share attributable to common stockholders-
Weighted-average number of common shares used in net loss per share attributable to Heat Biologics, Inc.-basic and diluted
Comprehensive loss:
Net loss
Unrealized (loss) gain on foreign currency translation
Total comprehensive loss
Comprehensive loss attributable to non-controlling interest
Comprehensive loss - Heat Biologics, Inc.

SOURCE: Heat Biologics, Inc.

View source version on

HEAT BIOLOGICS-Aktie komplett kostenlos handeln - auf
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.